Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Derma Sciences signs distribution agreement with MedEfficiency
According to MedEfficiency, the TCC-EZ cast will act as a protective barrier for the open wounds that often develop on the undersides of diabetic patients’ feet, and help
According to MedEfficiency, the TCC-EZ cast will act as a protective barrier for the open wounds that often develop on the undersides of diabetic patients’ feet, and help
Of 50 compounds identified, SF2523 and SF2506 have been chosen for additional evaluation based on their ability to inhibit multiple kinases, including PI3K, mTOR, DNA-PK and PIM-1. Evaluation
The company ended the trial as recommended by its independent data monitoring committee (IDMC) which observed an imbalance in deaths between the two treatment arms of the study.
Investors in the first closing of the private placement purchased 1.86 million shares of the company’s common stock at a price of $1.25 per share and received a
Pre-clinical studies have shown that Davanat, in combination with chemotherapy, significantly reduced tumor growth in mice implanted with metastatic human breast cancer. Results from similar pre-clinical studies designed
Dr Dolecek is currently Sucampo’s senior vice president of R&D. Dr Dolecek has received his BS from the University of Maryland and a MPH in health services and
According to the company, this non-dilutive financing is the next logical step after the $2.5 million equity financing by Innovatech Quebec, Lodial Capital, Fonds BioInnovation and Benoit Cote’s
The study showed that even single doses of Alpharadin in patients with painful bone metastases could produce increasing clinical benefit with increasing dose. The trial also confirmed Alpharadin’s
This randomized double blind, placebo controlled study aims to evaluate the safety and immunogenicity of the vaccine candidate in patients with end-stage kidney disease on hemodialysis. This trial
Toviaz (fesoterodine) is available as a 4mg and 8mg prolonged-release tablet. In trials, initial treatment effect was seen as early as two weeks after the start of therapy